1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Oneness Biotech Co., Ltd.

Oneness Biotech Co., Ltd.

7.40
USD
-0.05
(-0.67%)
0.02EPS
412.43P/E
788.06MMarket Cap
Nov 05Next Earn
Oneness Biotech Co., Ltd.
LUXSE:ONES
(Luxembourg Stock Exchange)

Recent

price

7.40

P/E

ratio

412.43

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
1.6
0.1
0.21
0.11
0.14
0.17
0.12
0.06
0.4
0.22
0.48
0.72
11.44
0.91
1.23
1.34
1.6
Revenue per Share
0.03
0.37
-0.66
6.76
5.01
-2.07
-0.3
-3.31
-5
-5.34
-2.82
-4.4
3.86
-13.83
-12.16
-10.87
0.63
Basic EPS, GAAP
3.73
-0.81
-1.85
-4.26
-3.91
-4.54
-5.56
-10.18
-3.66
-4.31
0.06
-4.25
-10.41
-5.41
-4.16
-5.07
-2.02
Free Cash Flow per Basic Share
0.33
- -
0.28
- -
0.65
0.4
- -
- -
- -
- -
- -
- -
- -
0.41
- -
- -
- -
Dividend per Share
26.66
34.11
43.79
47.83
46.86
59.13
53.79
49.9
43.13
75.19
151.39
151.92
155.85
147.23
128.37
107.57
106.64
Book Value per Share
26.45
33.58
43.23
47.27
46.36
58.66
53.3
49.41
42.03
44.87
122.94
125.07
133.47
128.68
116.03
97.25
97.35
Tangible Book Value per Share
37
38
41
41
40
45
47
47
47
60
86
92
93
95
96
96
96
Basic Weighted Avg Shares
59
4
9
5
5
8
6
3
19
13
42
66
1,066
87
118
129
154
Sales/Revenue/Turnover
-41.92
-2,083.42
-934.77
-2,668.58
-2,156.93
-1,239.74
-1,984.1
-5,376.61
-701.03
-2,313.42
-1,601.04
-1,335.27
-22.66
-1,263.64
-920.42
-618.85
-512.63
Operating Margin (%)
3
4
5
5
6
7
5
5
12
66
193
197
495
449
454
334
326
Depreciation Expense
1
14
-27
276
200
-93
-14
-155
-235
-322
-242
-403
360
-1,313
-1,165
-1,045
61
Net Income, GAAP
40.66
- -
- -
9.8
10.16
- -
- -
- -
- -
- -
- -
- -
22.08
- -
- -
- -
16.93
Effective Tax Rate (%)
1.61
375.67
-311.29
5,993.77
3,645.3
-1,186.29
-249.99
-6,008.74
-1,248.6
-2,391.14
-581.42
-613.25
33.78
-1,512.82
-988.03
-809.13
39.55
Profit Margin (%)
796
497
743
1,077
1,177
1,823
1,538
1,211
722
1,617
8,784
7,894
8,025
7,803
7,110
5,637
5,622
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
303
280
270
250
398
365
328
309
LT Debt
1,089
1,394
1,789
1,966
1,935
2,766
2,524
2,495
2,166
6,459
13,760
14,089
14,880
14,497
12,800
10,477
10,394
Total Equity
-1.34
- -
- -
-6.78
-5.35
- -
- -
- -
- -
- -
- -
- -
-1.27
- -
- -
- -
-5.89
Return on Invested Capital (%)
0.09
- -
- -
14.65
10.19
- -
- -
- -
- -
- -
- -
- -
2.52
- -
- -
- -
0.56
Return on Capital (%)
0.09
1.12
-1.68
14.71
10.24
-3.96
-0.54
-6.38
-10.75
-7.71
-2.42
-2.92
2.51
-9.16
-8.84
-9.23
0.59
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
43
44
44
LT Borrowings
- -
- -
- -
LT Finance Leases
328
317
309
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
96
96
96
Market Capitalization
26,633
25,008
25,093

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6,158
5,731
5,777
Cash, Cash Equivalents & STI
5,823
5,373
5,431
Accounts Receivable, Net
43
49
20
Inventories
111
108
109
Total Current Liabilities
521
151
155
Payables & Accruals
- -
- -
- -
ST Debt
43
44
44
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
26.38%
-4.88%
-18.15%
Free Cash Flow
-799.96%
-1,599.23%
22.03%
Net Income, GAAP
36.02%
-121.77%
-10.33%
Sales/Revenue/Turnover
225.9%
306.37%
9.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
26
31
29
31
118
2025
25
27
34
43
129
2026
37
40
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.97
-1.8
-5.29
-4.11
-12.16
2025
-1.69
-8.78
-0.03
-0.36
-10.87
2026
-1.56
2.59
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Oneness Biotech Co., Ltd. (4743.TWO) develops and commercializes novel biopharmaceuticals focused on chronic dermatology, immunology, infectious diseases, oncology, and metabolic disorders; the company offers Fespixon cream, a first-in-class macrophage-regulating treatment for diabetic foot ulcers approved in Taiwan, Macau, Singapore, Malaysia, China, and Indonesia with ongoing NDA submissions in Southeast Asia and a second Phase 3 trial in the US; it advances ON101 in Phase III for chronic diabetic foot ulcers, OB318 in Phase I as an anticancer botanical drug derived from antrodia cinnamomea, FB825 (anti-CεmX antibody) in Phase II for atopic dermatitis and allergic asthma following out-licensing to LEO Pharma, FB704A (anti-IL6 antibody) advancing to Phase II for rheumatoid arthritis after US FDA clearance, SNS812 in Phase II for COVID-19, and SNS851 for weight loss and metabolic diseases; Oneness further maintains a full-human antibody library, high-throughput screening platform, and monoclonal antibody development technologies alongside agricultural cultivation, trading, and production of related products. Founded in June 2008 and headquartered in Taipei, Taiwan, the company operates primarily in Taiwan with global clinical trials, regulatory approvals, and partnerships; it listed on the Taipei Exchange in September 2011 and employs approximately 43 people under CEO Shuling Cheng. Recent developments include Indonesia BPOM approval for Fespixon cream in July 2025 enabling market entry, sustained global expansion of Fespixon manufacturing via PIC/S GMP facilities in Pingtung Taiwan for API and finished products, progression of FB704A to Phase II clinical trials, and ongoing collaboration with LEO Pharma on FB825 to maximize development value; Oneness acquired Fountain Biopharma Inc. in August 2019 integrating immunology pipelines and resources for enhanced R&D and global competitiveness.